Global Lung Cancer Antibody Drug Conjugates Market Witnessing Exponential Growth Says Kuick Research Delhi, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Global Lung Cancer Antibody Drug Conjugates Market ...
Merck (MRK) and its Japanese partner Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to their investigational pipeline candidate, raludotatug deruxtecan ...
BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma This Becotatug Vedotin injection approval is BioDlink's ...
BioDlink announced that it has received a formal letter of appreciation from its client, Chengdu Kanghong Pharmaceutical Group ("Kanghong Pharmaceutical"), recognizing BioDlink's critical contribution ...
Company plans to initiate a Phase 1 clinical study by 1H2026 and share data in 2027 NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) ...
81% (17/21) of patients experienced ≥50% circulating tumor DNA reduction 50% (3/6) of patients with prior PSMA-targeted radionuclide therapy (TRT) experienced a ≥50% PSA reduction 50% (2/4) ...
From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech or the Company, 6990.HK) announced that a new indication ...
ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.
Merck MRK and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III HERTHENA-Breast04 study evaluating their investigational HER3-directed DXd antibody-drug conjugate (ADC) ...
Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results